Liver Diseases  >>  peginterferon lambda-1a (BMS-914143)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
peginterferon lambda-1a (BMS-914143) / Eiger, Stanford University
D-LITE, NCT01795911: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed
2b
165
US
Pegylated Interferon Lambda, BMS-914143, Ribasphere, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
04/14
09/14
D-LITE, NCT01309932 / 2010-022568-11: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE
More
Completed
2b
165
Japan, US, Europe, RoW
Pegylated Interferon Lambda (pegIFNλ), BMS-914143, BMS-790052 (NS5A Inhibitor), BMS-790052, Ribavirin (RBV), Ribasphere, BMS-650032 (NS3 Protease Inhibitor), BMS-650032, Pegylated Interferon Alfa-2a (pegIFNα-2a), Pegasys®, Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo for BMS-650032, Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for BMS-790052, Placebo for Ribavirin (RBV), Placebo for Ribasphere
Bristol-Myers Squibb
Hepatitis C
07/14
09/14
LIRA-B, NCT01204762 / 2010-020387-38: Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Completed
2
197
US, Canada, Europe, RoW
pegIFN, pegIFNα-2a, Pegasys, PegIFN lambda, BMS-914143, Entecavir, Baraclude
Bristol-Myers Squibb
Hepatitis B Virus
12/13
12/13

Download Options